MX2022012934A - Agente terapeutico para cancer de mama. - Google Patents
Agente terapeutico para cancer de mama.Info
- Publication number
- MX2022012934A MX2022012934A MX2022012934A MX2022012934A MX2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic agent
- breast cancer
- cancer therapeutic
- antiestrogens
- cdk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020074386 | 2020-04-17 | ||
| PCT/JP2021/015546 WO2021210636A1 (ja) | 2020-04-17 | 2021-04-15 | 乳がん治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012934A true MX2022012934A (es) | 2022-11-08 |
Family
ID=78084563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012934A MX2022012934A (es) | 2020-04-17 | 2021-04-15 | Agente terapeutico para cancer de mama. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230149381A1 (https=) |
| EP (1) | EP4122465A4 (https=) |
| JP (1) | JPWO2021210636A1 (https=) |
| KR (1) | KR20230004595A (https=) |
| CN (1) | CN115397415A (https=) |
| AU (1) | AU2021255084B2 (https=) |
| BR (1) | BR112022020786A2 (https=) |
| CA (1) | CA3180128A1 (https=) |
| MX (1) | MX2022012934A (https=) |
| WO (1) | WO2021210636A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| AU2021315234A1 (en) * | 2020-07-31 | 2023-01-19 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR094812A1 (es) * | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| JP2014235614A (ja) | 2013-06-03 | 2014-12-15 | 株式会社ゼネット | 総合学習支援ネットワークシステム及び総合学習支援方法 |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| JP2017217935A (ja) | 2016-06-03 | 2017-12-14 | 株式会社東海理化電機製作所 | ステアリングスイッチ装置 |
| JP2018022750A (ja) | 2016-08-02 | 2018-02-08 | 太陽誘電株式会社 | 積層セラミックコンデンサ |
| WO2018049233A1 (en) * | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
-
2021
- 2021-04-15 EP EP21787967.5A patent/EP4122465A4/en active Pending
- 2021-04-15 KR KR1020227039422A patent/KR20230004595A/ko active Pending
- 2021-04-15 JP JP2022515429A patent/JPWO2021210636A1/ja active Pending
- 2021-04-15 MX MX2022012934A patent/MX2022012934A/es unknown
- 2021-04-15 CA CA3180128A patent/CA3180128A1/en active Pending
- 2021-04-15 CN CN202180028460.3A patent/CN115397415A/zh active Pending
- 2021-04-15 US US17/918,829 patent/US20230149381A1/en not_active Abandoned
- 2021-04-15 BR BR112022020786A patent/BR112022020786A2/pt unknown
- 2021-04-15 WO PCT/JP2021/015546 patent/WO2021210636A1/ja not_active Ceased
- 2021-04-15 AU AU2021255084A patent/AU2021255084B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4122465A1 (en) | 2023-01-25 |
| US20230149381A1 (en) | 2023-05-18 |
| CA3180128A1 (en) | 2021-10-21 |
| BR112022020786A2 (pt) | 2022-11-29 |
| AU2021255084B2 (en) | 2026-04-02 |
| KR20230004595A (ko) | 2023-01-06 |
| CN115397415A (zh) | 2022-11-25 |
| AU2021255084A1 (en) | 2022-12-08 |
| JPWO2021210636A1 (https=) | 2021-10-21 |
| WO2021210636A1 (ja) | 2021-10-21 |
| EP4122465A4 (en) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012934A (es) | Agente terapeutico para cancer de mama. | |
| JOP20220282A1 (ar) | مركبات مفيدة لتثبيط كيناز ret | |
| SA520411007B1 (ar) | مركبات مضادة للتكاثر وطرق لاستخدامها | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2024014500A (es) | Inhibidores piridinicos de la cinasa 1 de puntos de regulacion (chk1) y usos de estos | |
| NZ603231A (en) | Cgrp receptor antagonist and its use for treating conditions such as migraine, neuropathic pain and proliferative diseases | |
| MX2023014028A (es) | Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. | |
| BR112022022753A2 (pt) | Métodos de fabricação de um composto bifuncional, formas ultrapuras do composto bifuncional e formas de dosagem compreendendo o mesmo | |
| MX2020013014A (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| US20160263113A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| PE20190377A1 (es) | Formulaciones de un inhibidor de lsd 1 | |
| SE0202462D0 (sv) | Novel use | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| JOP20240237A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| MX2024013020A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2023010314A (es) | Terapia de combinación usando un inhibidor de malt1 y un inhibidor de btk. | |
| RU2018119102A (ru) | Терапевтическое средство для лечения рака молочной железы | |
| PE20210417A1 (es) | Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende | |
| MX2023010268A (es) | Formas salinas novedosas de un inhibidor de cyp11a1 de estructura 4h-piran-4-ona. | |
| MX2023010322A (es) | Método para tratar una afección usando una dosis terapéuticamente efectiva del inhibidor de malt1 jnj-67856633 (1-(1-(1- oxo-1,2-dihidroisoquinolina-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piriidin-4-il)-1h-pirazol-4-carboxamida). | |
| MX2021010295A (es) | Nuevo inhibidor de cinasa pan-proteina de fibrosarcoma rapidamente acelerado (raf) y su uso. |